Revance Therapeutics Inc. (RVNC)

12.43
0.14 1.10
NASDAQ : Health Technology
Prev Close 12.57
Open 12.58
Day Low/High 12.24 / 12.72
52 Wk Low/High 10.37 / 30.60
Volume 168.00K
Avg Volume 399.40K
Exchange NASDAQ
Shares Outstanding 44.01M
Market Cap 538.65M
EPS -3.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Revance Adds Iconic Brand Builder Jill Beraud To Board Of Directors

Revance Adds Iconic Brand Builder Jill Beraud To Board Of Directors

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing a new category of high-performance neuromodulators for use in treating aesthetic and therapeutic conditions, today announced the appointment of Jill Beraud to the company's...

Revance To Participate In The Goldman Sachs 40th Annual Global Healthcare Conference

Revance To Participate In The Goldman Sachs 40th Annual Global Healthcare Conference

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company will participate in the Goldman Sachs 40th Annual...

Revance To Participate In The RBC Capital Markets 2019 Healthcare Conference

Revance To Participate In The RBC Capital Markets 2019 Healthcare Conference

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company will participate in the RBC Capital Markets 2019...

Revance Therapeutics Becomes Oversold (RVNC)

Revance Therapeutics Becomes Oversold (RVNC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Revance Reports First Quarter 2019 Financial Results And Provides Corporate Update

Revance Reports First Quarter 2019 Financial Results And Provides Corporate Update

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today reported financial results for the quarter ended March 31, 2019 and provided a...

Revance To Release First Quarter 2019 Financial Results On Wednesday, May 8, 2019

Revance To Release First Quarter 2019 Financial Results On Wednesday, May 8, 2019

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company will release first quarter 2018 financial results on...

Oversold Conditions For Revance Therapeutics (RVNC)

Oversold Conditions For Revance Therapeutics (RVNC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Revance Appoints Former Allergan Marketing Veteran Taryn Conway As Vice President Of Marketing

Revance Appoints Former Allergan Marketing Veteran Taryn Conway As Vice President Of Marketing

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced a pivotal addition to its leadership team with the appointment of Taryn...

SAKURA 3 Trial Results Presented On Podium At World's Largest Medical Aesthetic Conference

SAKURA 3 Trial Results Presented On Podium At World's Largest Medical Aesthetic Conference

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced podium and poster presentations of its SAKURA 3 Phase 3 open-label,...

Revance To Participate In The Needham Healthcare Conference

Revance To Participate In The Needham Healthcare Conference

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the Needham Healthcare Conference...

Revance To Participate In Upcoming Investor Conferences

Revance To Participate In Upcoming Investor Conferences

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in two upcoming investor conferences.

Revance Releases Fourth Quarter And Full Year 2018 Results

Revance Releases Fourth Quarter And Full Year 2018 Results

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced results for the fourth quarter and full year ended December 31, 2018...

Revance To Release Fourth Quarter And Full Year 2018 Financial Results On Tuesday, February 26, 2019

Revance To Release Fourth Quarter And Full Year 2018 Financial Results On Tuesday, February 26, 2019

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will release fourth quarter and full year 2018...

Revance Therapeutics Becomes Oversold (RVNC)

Revance Therapeutics Becomes Oversold (RVNC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Revance Announces Closing Of Public Offering Of Common Stock

Revance Announces Closing Of Public Offering Of Common Stock

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions ("Revance" or the "Company"), today announced the closing of an underwritten public...

Revance Announces Pricing Of Public Offering Of Common Stock

Revance Announces Pricing Of Public Offering Of Common Stock

Revance Therapeutics, Inc. (Nasdaq:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions ("Revance" or the "Company"), today announced the pricing of an underwritten public...

Revance Announces Proposed Public Offering Of Common Stock

Revance Announces Proposed Public Offering Of Common Stock

Revance Therapeutics, Inc. (Nasdaq:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions ("Revance" or the "Company"), today announced a proposed underwritten public offering in...

Revance Announces Ground-Breaking Data Presentations At Leading International Neurotoxin Conference

Revance Announces Ground-Breaking Data Presentations At Leading International Neurotoxin Conference

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced 11 clinical and non-clinical presentations for DaxibotulinumtoxinA for...

Revance Highlights Recent Regulatory Progress And Provides Anticipated 2019 Milestones

Revance Highlights Recent Regulatory Progress And Provides Anticipated 2019 Milestones

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced updates on meetings with the U.

First Week Of July 2019 Options Trading For Revance Therapeutics (RVNC)

First Week Of July 2019 Options Trading For Revance Therapeutics (RVNC)

Investors in Revance Therapeutics Inc saw new options become available this week, for the July 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 224 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Revance Announces China Market License Agreement With Fosun Pharma For RT002

Revance Announces China Market License Agreement With Fosun Pharma For RT002

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company has entered into a license agreement with Shanghai...

Revance's RT002 Demonstrates Unprecedented Efficacy And Duration In Largest-Ever Aesthetic Neuromodulator Clinical Program

Revance's RT002 Demonstrates Unprecedented Efficacy And Duration In Largest-Ever Aesthetic Neuromodulator Clinical Program

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced its long-acting neuromodulator DaxibotulinumtoxinA for Injection (RT002)...

Revance To Participate In Upcoming Investor Conferences

Revance To Participate In Upcoming Investor Conferences

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in two upcoming investor conferences.

Revance To Participate In The Credit Suisse Healthcare Conference

Revance To Participate In The Credit Suisse Healthcare Conference

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the Credit Suisse Healthcare...

Revance Releases Third Quarter 2018 Results

Revance Releases Third Quarter 2018 Results

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced results for the third quarter ended September 30, 2018.

Revance Therapeutics To Release Third Quarter 2018 Financial Results On Thursday, November 1, 2018

Revance Therapeutics To Release Third Quarter 2018 Financial Results On Thursday, November 1, 2018

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will release second quarter 2018 financial results on Thursday,...

Revance Therapeutics Appoints Tobin C. Schilke As Chief Financial Officer

Revance Therapeutics Appoints Tobin C. Schilke As Chief Financial Officer

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that it has strengthened its leadership team with the appointment of Tobin C.

Revance To Participate In The Cantor Fitzgerald 2018 Global Healthcare Conference

Revance To Participate In The Cantor Fitzgerald 2018 Global Healthcare Conference

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the Cantor Fitzgerald 2018 Global Healthcare...

TheStreet Quant Rating: D (Sell)